ASN: Bardoxolone methyl no benefit in T2DM, stage 4 CKD

ASN: bardoxolone methyl no benefit in T2DM, stage 4 CKD

(HealthDay)—Bardoxolone methyl does not reduce the risk of end-stage renal disease (ESRD) or cardiovascular death in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease, according to a study published online Nov. 9 in the New England Journal of Medicine. This research was published to coincide with the annual meeting of the American Society of Nephrology (Kidney Week), held from Nov. 5 to 10 in Atlanta.

Dick de Zeeuw, M.D., Ph.D., from the University of Groningen in the Netherlands, and colleagues randomized 2,185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease to receive bardoxolone methyl or placebo. Participants were followed for the primary composite outcome of ESRD or .

On the recommendation of the independent data and safety monitoring committee, the trial was terminated early, with a median follow-up of nine months. The researchers found that the primary composite outcome occurred in 6 percent of the 1,088 patients assigned to bardoxolone methyl and 6 percent of the 1,097 assigned to placebo. Significantly more patients in the bardoxolone methyl group were hospitalized for or died from heart failure compared with the (96 versus 55 patients; hazard ratio, 1.83).

"Among patients with type 2 diabetes mellitus and stage 4 , bardoxolone methyl did not reduce the risk of ESRD or death from cardiovascular causes," the authors write.

The study was funded by Reata Pharmaceuticals, a manufacturer of bardoxolone methyl.

More information: Abstract
Full Text
Editorial
More Information

Journal information: New England Journal of Medicine

Copyright © 2013 HealthDay. All rights reserved.

Citation: ASN: Bardoxolone methyl no benefit in T2DM, stage 4 CKD (2013, November 11) retrieved 18 March 2024 from https://medicalxpress.com/news/2013-11-asn-bardoxolone-methyl-benefit-t2dm.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Drug shows improved kidney function for type 2 diabetics

 shares

Feedback to editors